Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 216 for “"small cell lung cancer"”.
-
Radiotherapy in Non-Small-Cell Lung Cancer
Contains fulltext : 30924_radiinnol.pdf (Publisher’s version ) (Open Access)
-
Neutrophils in advanced non-small cell lung cancer
Lung cancer is the third most common cancer in the UK; 87% are histologically nonsmall cell lung cancer (NSCLC). At the time of diagnosis, patients frequently have advanced disease, with poor one-year survival due to metastatic burden. The immune system should act as a key line of defence; …
-
CRISPR-mediated interrogation of small cell lung cancer
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung carcinoma that remains among the most lethal of solid tumor malignancies. Despite decades of research, treatment outcomes for SCLC remain very poor, highlighting the need for novel approaches to target the disease. Recent …
-
Enhancing Radiation Sensitivity In Non-Small Cell Lung Cancer
<p>Lung cancer is the leading cause of cancer-related death. While radiation therapy is one of the standard treatments for lung cancer, the disease outcome after radiotherapy is still far from satisfactory despite ongoing advances in radiation techniques. Enhancing the radiosensitivity of lung …
-
Peptide Targeted Drug Delivery to Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a notoriously deadly disease. The integrin αᵥβ₆ is emerging as a viable target for NSCLC; it is expressed in more than half of NSCLC patient tumor samples and only rarely expressed in normal tissue. Importantly, αᵥβ₆ is turned on early in the disease …
-
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells
Cancer cells display oncogene-driven rewiring of metabolism to produce energy and macromolecules for growth. Inhibition of growth-promoting metabolic pathways may prove to be a useful therapeutic strategy in cancer. However, neither the full breadth of cancer cell metabolic diversity, nor the …
-
Investigating the initiation and progression of small cell lung cancer
Small cell lung cancer (SCLC) comprises 18% of all lung cancer cases and is an aggressive disease with a five-year survival rate of less than 5%, mainly due to the advanced nature of the disease at the time of diagnosis. Despite the need to better understand this disease, the genetic lesions that …
-
Effect of Tumor Microenvironmental Conditions on Non Small Cell Lung Cancer
… recurrence. Due to inefficient vasculature, cancer cells experience hypoxia, glucose deprivation and low pH even during the early stages of tumor growth. Tumor cells are proposed to adapt to these microenvironmental conditions by acquiring increased migratory and invasion potential and tumor …
-
Development of Afatinib lipid nanoparticles targeting non small cell lung cancer
Lung cancer is the most common cause of cancer-associated mortality in males and females globally. Widespread research is currently focused on the development of novel approaches for targeting non small cell lung cancer with different therapeutic nanotechnologies. In this study, a sensitive and …
-
Mechanisms of Sensitization to Chemotherapy in Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths world-wide for men and women, due in part to late detection of disease and inherent resistance to treatment. This body of work focuses on resistance to treatment, specifically chemotherapy and understanding ways to sensitize non-small cell …
-
Identification of Oncogenic KRAS-Associated Vulnerabilities in Non-Small Cell Lung Cancer
… frequently involved in the pathogenesis of non-small cell lung cancer (NSCLC), the disease responsible for the most cancer-related deaths in the US. Despite intensive efforts to develop drugs that directly interfere with KRAS activity over the past decade, no effective inhibitor has been …
-
Hedgehog signaling: a potential therapeutic target for non-small cell lung cancer
<p>The American Cancer Society estimated that 222,520 Americans were diagnosed with lung cancer and 157,300 died of lung cancer in 2010 (Jemal et al. 2009, 225-249;Jemal et al. 2011, 69-90). The clinical outcome of patients diagnosed with non-small cell lung cancer (NSCLC), the major lung cancer …
-
Preclinical Studies of Telomerase Inhibitor Imetelstat in Non-small Cell Lung Cancer
Telomerase is expressed in ~90% of all cancers but is not expressed in most somatic cells making it an attractive target for cancer therapy. Telomerase has two essential components, a reverse transcriptase (hTERT) and an RNA template (hTR or hTERC). The RNA template is used by the reverse …
-
Genetic Predictors of Clinical Outcomes In Non-Small Cell Lung Cancer Patients
<p>Lung cancer is the leading cause of cancer-related mortality in the US. Emerging evidence has shown that host genetic factors can interact with environmental exposures to influence patient susceptibility to the diseases as well as clinical outcomes, such as survival and recurrence. We aimed to …
-
Histone Lysine Demethylase KDM4A as a Therapeutic Target for Small Cell Lung Cancer
Small cell lung cancer (SCLC) arises from neuroendocrine cells within the lung. Along with deletion or loss-of-function RB1 and TP53 mutations, which occur in almost all cases, subsets of SCLC are driven by specific lineage transcription factors including ASCL1, NEUROD1, POU2F3, or YAP1. The …
-
Characterization of mTOR Inhibition and Autophagy Inhibition in Non-Small Cell Lung Cancer
Lung cancer continues to be the leading cause of cancer related death in both men and women. Pre-clinical studies of targeted therapies are needed in order to improve upon the chemotherapeutics that are currently in use. The ability to identify subsets of patient tumors which will respond to a …
-
Elucidating the Target and Selectivity of a Non-Small Cell Lung Cancer Toxin
Selective toxicity among cancer cells of the same lineage is a hallmark of targeted therapies, and so identifying compounds that impair proliferation selectively is an important strategy in drug development. Here, we report the discovery of the quinazoline dione compound (QDC), a molecule that …
Page 1 of 11